FDA regulatory pathways and what licensing BIEL’s already-cleared technology could mean for Electrome:
FDA Clearance Timelines
New device development (Electrome on its own):
Preclinical R&
1–2 years (signal discovery, prototypes, safety testing).
Clinical trials: 2–4 years depending on indication (pain, infection, cancer).
FDA submission & review:
510(k) clearance (if substantially equivalent to existing devices): ~6–12 months.
De Novo or PMA (new class/high risk): 2–5 years.
Total timeline: 4–7 years from concept to clearance.
Licensing BIEL’s FDA-cleared PSWT technology:
BIEL already has 510(k)-cleared devices (e.g., RecoveryRx, ActiPatch).
Electrome could piggyback on existing clearances or file a supplemental 510(k) for modifications.
Supplemental clearances typically take 6–12 months, not years.
Total timeline: 1–2 years to adapt and integrate, instead of 4–7 years.
Estimated Time Saved
Electrome alone: 4–7 years.
Electrome licensing BIEL: 1–2 years.
Time saved: 3–5 years on average.
Strategic Impact
For Electrome: Faster market entry, reduced regulatory risk, ability to focus on AI/digital twin innovation rather than hardware validation.
For BIEL: Licensing fees, royalties, and validation of its PSWT technology.
For the industry: Accelerated adoption of bioelectric medicine by combining proven device platforms with next-gen AI therapeutics.
Bottom line: Electrome could save 3–5 years of regulatory time by licensing BIEL’s already-cleared technology instead of pursuing entirely new FDA approvals.
FDA Clearance Timelines
New device development (Electrome on its own):
Preclinical R&
1–2 years (signal discovery, prototypes, safety testing). Clinical trials: 2–4 years depending on indication (pain, infection, cancer).
FDA submission & review:
510(k) clearance (if substantially equivalent to existing devices): ~6–12 months.
De Novo or PMA (new class/high risk): 2–5 years.
Total timeline: 4–7 years from concept to clearance.
Licensing BIEL’s FDA-cleared PSWT technology:
BIEL already has 510(k)-cleared devices (e.g., RecoveryRx, ActiPatch).
Electrome could piggyback on existing clearances or file a supplemental 510(k) for modifications.
Supplemental clearances typically take 6–12 months, not years.
Total timeline: 1–2 years to adapt and integrate, instead of 4–7 years.
Estimated Time Saved
Electrome alone: 4–7 years.
Electrome licensing BIEL: 1–2 years.
Time saved: 3–5 years on average.
Strategic Impact
For Electrome: Faster market entry, reduced regulatory risk, ability to focus on AI/digital twin innovation rather than hardware validation.
For BIEL: Licensing fees, royalties, and validation of its PSWT technology.
For the industry: Accelerated adoption of bioelectric medicine by combining proven device platforms with next-gen AI therapeutics.
Bottom line: Electrome could save 3–5 years of regulatory time by licensing BIEL’s already-cleared technology instead of pursuing entirely new FDA approvals.
1
